Int. J. Mol. Sci. 2014, 15(12), 23024-23041; https://doi.org/10.3390/ijms151223024
Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer
1
Department of Biomedicine, Pharmacology, Aarhus University, Wilhelm Meyers Allé 4, Aarhus C 8000, Denmark
2
Clinic for Plastic, Aesthetic and Hand Surgery, Otto-von-Guericke-University Magdeburg, Leipziger Str. 44, Magdeburg D-39120, Germany
3
Department of Oncology, Aarhus University Hospital, Nørrebrogade 44, Aarhus C 8000, Denmark
4
Medical Research Laboratory, Department of Clinical Medicine, Aarhus University, Nørrebrogade 44, Aarhus C 8000, Denmark
†
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Received: 26 October 2014 / Revised: 5 December 2014 / Accepted: 6 December 2014 / Published: 11 December 2014
(This article belongs to the Collection Advances in Proteomic Research)
Abstract
Neo-angiogenesis is a critical process for tumor growth and invasion and has become a promising target in cancer therapy. This manuscript reviews three currently relevant anti-angiogenic agents targeting the vascular endothelial growth factor system: bevacizumab, ramucirumab and sorafenib. The efficacy of anti-angiogenic drugs in adjuvant therapy or as neo-adjuvant treatment has been estimated in clinical trials of advanced breast cancer. To date, the overall observed clinical improvements are unconvincing, and further research is required to demonstrate the efficacy of anti-angiogenic drugs in breast cancer treatments. The outcomes of anti-angiogenic therapy have been highly variable in terms of tumor response. New methods are needed to identify patients who will benefit from this regimen. The development of biomarkers and molecular profiling are relevant research areas that may strengthen the ability to focus anti-angiogenic therapy towards suitable patients, thereby increase the cost-effectiveness, currently estimated to be inadequate. View Full-Text
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Kristensen, T.B.; Knutsson, M.L.T.; Wehland, M.; Laursen, B.E.; Grimm, D.; Warnke, E.; Magnusson, N.E. Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer. Int. J. Mol. Sci. 2014, 15, 23024-23041.
Related Articles
Article Metrics
Comments
[Return to top]
Int. J. Mol. Sci.
EISSN 1422-0067
Published by MDPI AG, Basel, Switzerland
RSS
E-Mail Table of Contents Alert